Invest1 publisher2 min readPublished
ChronoScale's $1 billion contract run-rate is 14 times the revenue it booked last year
ChronoScale says its signed AI compute contracts now annualize to $1 billion, against $71.6 million of revenue in its last fiscal year. The figure counts signed agreements, so the stock depends on capacity still being built turning them into cash.
The Investor · Invest desk
What happened
- ChronoScale announced on October 1 that it is selling its legacy Ekso Bionics exoskeleton business, on the same day it extended one AI client deal and signed another.
- The company itself dates only to May 2026, when Applied Digital's cloud business merged with Ekso Bionics Holdings.
- Most of its revenue in the fiscal year to May 31, 2026 came from one customer, Together AI, under a recurring contract.
- Microsoft signed for 50 megawatts of NVIDIA GB300 NVL72 capacity in North America, with ChronoScale targeting completion of the build by Q1 2027.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- constraint With Ekso sold, no cash or management time goes to wearable robotics, and CHRN holders own a single bet on compute delivery with no second business to cushion a late build.
- exposure Until the newly contracted capacity is running and billing, ChronoScale's reported revenue will keep reflecting last year's reliance on Together AI, whatever the signed contracts show.
- cost Whoever funds the 50 MW GB300 build, lenders or buyers of new shares, will take part of the contracted revenue that current CHRN holders are counting on.
Run-rate figures typically annualize the value of signed agreements, Crypto Briefing noted in its report on the deals, so they measure what is lined up and not cash already collected [3]. ChronoScale reported $71.6 million of revenue for the fiscal year that ended May 31, 2026 [5]. The $1 billion figure [1] is about 14 times that [1]. The difference, roughly $928 million a year [3], is the distance between what the company has signed and what it last reported.
ChronoScale has also set a goal of $1 billion in revenue by Q3 2027 [4]. Its contracts already reach that number on paper, so the goal is in effect a date for turning signatures into reported sales. If the goal means an annualized pace, it implies about $250 million of revenue a quarter [4]. A single quarter at that pace would bring in roughly 3.5 times what the company booked in the whole of its last fiscal year [5].
The company is still losing money at a high rate. Its net loss for that fiscal year was approximately $50.3 million [7], or about 70 cents for every dollar of revenue [2]. Crypto Briefing's report does not identify the clients behind the October 1 contracts or say how long those contracts run, and it does not include a price for Ekso.
The people responsible for delivery were all appointed in 2026. Cenly Chen became chief executive in May, and Raj Jegannathan and Lawrence Lam joined as chief technology officer and chief product officer in June [11].
The Microsoft capacity could come online on schedule, with quarterly revenue climbing toward that $250 million pace [4]. The build could run late, and the loss would keep building against a revenue base that still looks like last year's. Or the capacity could arrive and revenue rise while the company still loses about 70 cents on each dollar of revenue [2].
I think the $1 billion is an accurate count of signed work. It is a poor guide to what the stock is worth until the first quarter after the Microsoft completion date [9]. The argument against that view is that the contracts are signed and the biggest name on the client list is Microsoft [8], which would make the open question one of timing more than whether the cash arrives. The view would be proved wrong if reported quarterly revenue moves toward $250 million [4] by Q3 2027 [4] while the loss falls well below 70 cents per revenue dollar [2].
What to watch
- ChronoScale's next quarterly report, and whether revenue is moving off last year's base before any Microsoft capacity is running.
- The buyer and price for the Ekso Bionics business, and whether the proceeds go into the compute build.
- Whether ChronoScale defines its Q3 2027 goal as an annualized pace or as revenue booked over a period.